医保目录新增一类新药芪防鼻通片，用于治疗过敏性鼻炎

Core Viewpoint - Yiling Pharmaceutical's innovative traditional Chinese medicine, Qifang Nizhong Pian, has been included in the National Medical Insurance Directory for 2025, marking a significant recognition of its innovation and clinical efficacy in treating allergic rhinitis [1] Group 1: Product Inclusion and Market Impact - Qifang Nizhong Pian is one of 12 exclusive products from Yiling Pharmaceutical included in the national medical insurance directory [1] - The recent adjustment added 114 new drugs, with 50 being innovative drugs, indicating a strong policy support for "true innovation" in the pharmaceutical industry [1] Group 2: Clinical Efficacy and Research Support - Qifang Nizhong Pian has demonstrated significant efficacy in treating persistent allergic rhinitis, with a total clinical symptom improvement rate of 74.71% and a patient satisfaction improvement rate of 89% [3] - The drug's safety and efficacy were validated through randomized, double-blind, placebo-controlled, multi-center Phase II and III clinical trials, published in the international journal "Ethnopharmacology" [3] Group 3: Mechanism of Action and Advantages - The pharmacological mechanisms of Qifang Nizhong Pian include anti-allergic, anti-inflammatory, immune regulation, and improvement of nasal mucosal tissue damage, supporting its "holistic treatment" approach [4] - Compared to other treatments for allergic rhinitis, Qifang Nizhong Pian offers comprehensive regulation, improving both local and systemic symptoms, thus aiding patients in quickly resuming their daily activities [4] Group 4: Additional Products - In addition to Qifang Nizhong Pian, Yiling Pharmaceutical has 11 other exclusive products, including Tongxinluo, Ginseng Pine Heart Capsules, and Lianhua Qingwen, that have also entered the new medical insurance directory [4]